Piia Valonen
Overview
Explore the profile of Piia Valonen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lesch H, Valonen P, Karhinen M
Biotechnol J
. 2020 Sep;
16(1):e2000020.
PMID: 32971565
The accelerating development of gene therapy from research towards clinical trials and beyond has elevated the demand for practical viral vector-manufacturing solutions. The use of disposable upstream technology is gaining...
2.
Huuskonen M, Loppi S, Dhungana H, Keksa-Goldsteine V, Lemarchant S, Korhonen P, et al.
Sci Rep
. 2016 Sep;
6:33176.
PMID: 27624652
Stroke is a highly debilitating, often fatal disorder for which current therapies are suitable for only a minor fraction of patients. Discovery of novel, effective therapies is hampered by the...
3.
Rolova T, Dhungana H, Korhonen P, Valonen P, Kolosowska N, Konttinen H, et al.
Aging Dis
. 2016 Aug;
7(4):450-65.
PMID: 27493832
Transient forebrain ischemia induces delayed death of the hippocampal pyramidal neurons, particularly in the CA2 and medial CA1 area. Early pharmacological inhibition of inflammatory response can ameliorate neuronal death, but...
4.
Lemarchant S, Pomeshchik Y, Kidin I, Karkkainen V, Valonen P, Lehtonen S, et al.
Mol Neurodegener
. 2016 Feb;
11:15.
PMID: 26858022
No abstract available.
5.
Lemarchant S, Pomeshchik Y, Kidin I, Karkkainen V, Valonen P, Lehtonen S, et al.
Mol Neurodegener
. 2016 Jan;
11:10.
PMID: 26809777
Background: A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) proteoglycanases are specialized in the degradation of chondroitin sulfate proteoglycans and participate in mechanisms mediating neuroplasticity. Despite the beneficial effect of...
6.
Lesch H, Heikkila K, Lipponen E, Valonen P, Muller A, Rasanen E, et al.
Hum Gene Ther
. 2015 Jul;
26(8):560-71.
PMID: 26176404
Large-scale vector manufacturing for phase III and beyond has proven to be challenging. Upscaling the process with suspension cells is increasingly feasible, but many viral production applications are still applicable...
7.
Dhungana H, Malm T, Denes A, Valonen P, Wojciechowski S, Magga J, et al.
Aging Cell
. 2013 Jun;
12(5):842-50.
PMID: 23725345
Ischemic stroke is confounded by conditions such as atherosclerosis, diabetes, and infection, all of which alter peripheral inflammatory processes with concomitant impact on stroke outcome. The majority of the stroke...
8.
Jaronen M, Vehvilainen P, Malm T, Keksa-Goldsteine V, Pollari E, Valonen P, et al.
Hum Mol Genet
. 2012 Nov;
22(4):646-55.
PMID: 23118353
Protein disulfide isomerase (PDI) is an oxidoreductase assisting oxidative protein folding in the endoplasmic reticulum of all types of cells, including neurons and glia. In neurodegenerative disorders, such as amyotrophic...
9.
Varmavuo V, Mantymaa P, Nousiainen T, Valonen P, Kuittinen T, Jantunen E
Eur J Haematol
. 2012 Apr;
89(2):128-35.
PMID: 22536949
Background: Plerixafor is used to mobilize CD34(+) hematopoietic stem cells from bone marrow to circulation. Limited data are available in regard to graft cellular content collected after plerixafor. Objectives: The...
10.
Magga J, Savchenko E, Malm T, Rolova T, Pollari E, Valonen P, et al.
J Cell Mol Med
. 2011 Jul;
16(5):1060-73.
PMID: 21777378
Accumulation of amyloid β (Aβ) is a major hallmark in Alzheimer's disease (AD). Bone marrow derived monocytic cells (BMM) have been shown to reduce Aβ burden in mouse models of...